

VIVALIS ANNOUNCES A NEW AND NOVEL EB66[®] CELL LINE DEVELOPMENT AGREEMENT

Nantes & Lyon (France) – 31 July 2012 – Vivalis (NYSE Euronext: VLS) announced today that it has signed a new cell line development agreement with an undisclosed party utilizing Vivalis' proprietary EB66[®] cell line. This contract represents a new application of EB66[®] cells to create a complementing cell line for a replication-defective, virus-based vaccine candidate for human use.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of Vivalis jointly stated, "Advancing the EB66[®] cell line into new areas has been an objective since the launch of the EB66[®] platform in 2007. This approach for vaccine development is also under investigation or consideration with other Vivalis customers, where EB66[®] cells serve as the base substrate for new, virus complementing cell lines. Principally shared amongst these customers is the recognized value of the very strong industrial characteristics and the traceability and documented history that EB66[®] cells provide from the start, a heavily invested effort that Vivalis continues to this day. We look forward to the progression of this new platform and an expanded agreement with this and other customers upon their success."

Terms of the agreement were not disclosed.

Next Financial Press Release

August 30, 2012, after NYSE Euronext market closing: First Half 2012 Results

About Vivalis (www.vivalis.com)

Vivalis (Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. Vivalis's expertise and intellectual property are leveraged in two main areas:

EB66[®] Cell Line

Vivalis offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66[®] cell line based vaccines are currently in clinical trials in the USA and Japan. Through these programs Vivalis receives upfront, clinical stage milestone payments along with royalties on licensees net sales.

VIVA|Screen[™] Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of rare, fully human monoclonal antibodies is now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees net sales.

Based in Nantes & Lyon (France) and in Toyama (Japan), VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,700 employees), a worldwide leader in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine Merial, Merck Animal Health, SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bioclusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

Vivalis

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indices



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

Vivalis

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tél.: +33 (0) 1 44 71 94 91

Email : vivalis@newcap.fr